DeepHealth, a RadNet subsidiary, received FDA clearance for its AI solution to assist prostate cancer detection and MRI workflow.
Key Details
- 1FDA cleared DeepHealth's Prostate Suite, an AI platform for prostate MRI workflows.
- 2Tool provides AI assistance for lesion detection, risk assessment, segmentation, and PI-RADS reporting.
- 3Compatible with 11 fusion biopsy systems, integrating with radiologists' existing tools.
- 4Real-world use: detected 27% more lesions, reduced segmentation variability by 65%, and cut biopsy workflow times by 37%.
- 5RadNet also received CE Mark in Europe for Brain Health, Brain Age, and LumbarMR AI solutions.
- 6LumbarMR AI supports lumbar spine MRI analysis, added through Gleamer acquisition.
Why It Matters
FDA clearance signals increasing acceptance and integration of AI tools in radiology. These solutions may meaningfully improve cancer detection accuracy, workflow efficiency, and broader access to prostate and other disease screenings.
Source
Radiology Business
Related News
•Radiology Business
AI Predicts Breast Cancer Up to Six Years Before Diagnosis
AI technology using mammograms can predict breast cancer risk up to six years in advance.
•AuntMinnie
AI-Based Slab Reconstruction Streamlines Digital Breast Tomosynthesis
AI-driven slab reconstruction in DBT improves workflow efficiency without compromising diagnostic accuracy in breast cancer screening.
•Radiology Business
Subtle Medical Raises $33M for AI Imaging Workflow Expansion
Subtle Medical secured $33 million to accelerate its AI image enhancement solutions for radiology.